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ABSTRACT
Introduction: The National Institute for Health and
Care Excellence (NICE) guidelines for attention deficit/
hyperactivity disorder (ADHD) state that young people
need to have access to the best evidence-based care to
improve outcome. The current ‘gold standard’ ADHD
diagnostic assessment combines clinical observation
with subjective parent, teacher and self-reports. In
routine practice, reports from multiple informants may
be unavailable or contradictory, leading to diagnostic
uncertainty and delay. The addition of objective tests of
attention and activity may help reduce diagnostic
uncertainty and delays in initiating treatment leading to
improved outcomes. This trial investigates whether
providing clinicians with an objective report of levels of
attention, impulsivity and activity can lead to an earlier,
and more accurate, clinical diagnosis and improved
patient outcome.
Methods and analysis: This multisite randomised
controlled trial will recruit young people (aged 6–
17 years old) who have been referred for an ADHD
diagnostic assessment at Child and Adolescent Mental
Health Services (CAMHS) and Community Paediatric
clinics across England. Routine clinical assessment will
be augmented by the QbTest, incorporating a
continuous performance test (CPT) and infrared
motion tracking of activity. The participant will be
randomised into one of two study arms: QbOpen
(clinician has immediate access to a QbTest report):
QbBlind (report is withheld until the study end).
Primary outcomes are time to diagnosis and diagnostic
accuracy. Secondary outcomes include clinician’s
diagnostic confidence and routine clinical outcome
measures. Cost-effective analysis will be conducted,
alongside a qualitative assessment of the feasibility and
acceptability of incorporating QbTest in routine
practice.
Ethics and dissemination: The findings from the
study will inform commissioners, clinicians and
managers about the feasibility, acceptability, clinical
utility and cost-effectiveness of incorporating QbTest
into routine diagnostic assessment of young people
with ADHD. The results will be submitted for
publication in peer-reviewed journals. The study has
received ethical approval.
Trial registration number: NCT02209116.
INTRODUCTION
Attention deﬁcit/hyperactivity disorder
(ADHD) is the most common neurodevelop-
mental disorder and affects 3–5% of children
and young people.1 The core symptoms of
ADHD include poor attention, hyperactivity
and impulsivity. National Institute for Health
and Care Excellence (NICE)1 guidelines
provide a blueprint for the diagnosis and
Strengths and limitations of this study
▪ A pragmatic diagnostic randomised controlled
trial design in standard National Health Service
(NHS) settings.
▪ The focus of the trial is the impact of an object-
ive assessment technology on clinical decision
making and patient outcomes.
▪ There is limited data regarding the clinical utility,
cost-effectiveness and acceptability of using the
QbTest to aid attention deficit/hyperactivity dis-
order assessment and treatment.
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management of ADHD in England and Wales and indi-
cate the need for young people with ADHD to have
access to the best evidence-based care in order to fulﬁl
their potential and prevent poor outcome. However, in
practice, delivery and quality of care is ad hoc, with little
consistency in assessment, diagnosis or management.2
ADHD frequently coexists with other neurodevelopmen-
tal and psychiatric disorders and is a risk factor for
major educational, social and occupational impairment,
placing a huge burden on the National Health Service
(NHS), social care and criminal justice systems. There
has been a rapid growth in diagnosis over the past
30 years with the number of children recognised and
treated for ADHD in the UK increasing almost 10-fold
from the early 1980s1 and spending on medication for
ADHD increasing sevenfold between 1998 and 2005.3
The cost of initial specialist assessment for ADHD is esti-
mated at £23 million annually in England and Wales4
and drug costs for ADHD in England during 2012 was
expected to exceed £78 million3 while indirect costs to
families include parental mental ill health, time off work
and loss of earnings are even higher.5 Increasing recog-
nition of ADHD as a lifespan condition is placing a new
demand on the NHS to provide diagnostic and treat-
ment services for children, adolescents and adults,
exposing serious limitations in existing methods of
assessment and management.
There is no single test, or biomarker used to diagnose
the disorder.6 In the absence of any objective measure
to identify ADHD, clinical assessment and diagnosis is
based on the clinician’s integration of various forms of
subjective information including direct observation and
reports from parents, teachers and young people. This
approach is heavily reliant on subjective measures and
clinical interpretation, which can lead to lack of reliabil-
ity and consistency in the diagnosis of ADHD7 and fur-
thermore, the process of ‘gold standard’ clinical
interviews and data collection from multiple informants
is time consuming and often difﬁcult to conduct in real
world settings with frequent missing data and inconsist-
encies between reports leading to and diagnostic uncer-
tainty and delay.
Additionally, while treatments for ADHD are highly
efﬁcacious in carefully managed research settings1 in
standard community care the outcome of treatment may
be suboptimal. Aside from delays in initiating treatment
caused by diagnostic uncertainty, once on medication,
children may not be reviewed sufﬁciently frequently for
clinicians to detect non-response or partial response, or
to establish the optimal dose for each child. The US
National Institute of Mental Health (NIMH) Multimodal
Treatment study of ADHD (MTA) showed that careful
medication management can signiﬁcantly improve out-
comes, doubling the normalisation rate from 25% in
routine community care to almost 60% when using a
strategy of careful dose titration and frequent monitor-
ing of outcome.8 The NICE1 ADHD guidelines recom-
mends that during the titration phase, symptoms should
be closely monitored using rating scales. However, audit
data within the East Midlands showed that community
care for ADHD falls well below the standards for titra-
tion and monitoring set out in the MTA and NICE
guidelines (CLAHRC-NDL, 2013, unpublished audit). A
further consequence of suboptimal treatment response
in routine care is poor medication adherence. In the
UK, 50% of patients have stopped ADHD medication
after 18 months and 80% after 3 years.9
Objective assessment measures in ADHD
One approach to improving assessment and outcomes
in routine care is to add objective laboratory measures
of activity and attention for diagnostic assessment and
treatment optimisation.5 Objective measures have the
potential to augment and streamline current practice in
order to shorten assessment time, increase diagnostic
accuracy, reduce delays in treatment and optimise treat-
ment response.
Continuous performance test
A continuous performance test (CPT) is a neuropsycho-
logical test that measures the individual’s capacity to
sustain attention (vigilance) and inhibit inappropriate
responses (impulsivity), which can be used alongside
clinical evaluation to inform the diagnostic process.10
Typically, a CPT is a computer-based programme which
involves rapid presentation of visual or auditory stimuli.
Participants are asked to respond when a given target
occurs but remain passive to non-targets. A standard
CPT typically records the child’s omission errors
(responding when the target is present), commission
errors (responding when the target is not present),
number of correct responses, reaction time and variabil-
ity in reaction time. There are several well validated
commercially available CPT tests such as the TOVA (Test
of Variables of Attention11), IVA (Integrated Visual and
Auditory12), ACPT (Auditory CPT13) and the Conner’s
CPT.14 These tests are one of the most popular clinic-
based measures to assess sustained attention in chil-
dren;15 with several studies and a meta-analyses showing
that children with ADHD perform worse on these tasks
than children without ADHD.16 CPTs have also been
shown to be a sensitive measure of medication effects.17
Several studies have noted improvement in CPT scores
in children with ADHD on stimulant medication.15 18–20
However, little research has compared CPT scores with
more subjective measurements of ADHD7 and in their
recent review Ogundele et al7 recommended further
research in the use of CPTs compared to standard prac-
tice to determine cost-effectiveness of these tasks.
A signiﬁcant limitation of the CPT for the assessment
of ADHD is that it does not measure the patients’ activity
levels, which is a core symptom domain of ADHD.
Approaches to the objective measurement of activity in
ADHD have included wrist-worn actigraphy devices and
infra-red motion capture.
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QbTest
QbTest (Qbtech Ltd) has been developed to combine a
CPT to measure attention and impulsivity with infra-red
motion capture of head movement during the CPT to
measure activity.21 The QbTest CPT requires participants
to respond to an infrequently presented stimulus (by
pressing a button) but ignore all others. Physical activity
is measured during the course of the CPT via an infra-
red camera that tracks the path of a reﬂector attached to
the participants head (central midpoint). These ele-
ments of the test provide information on each of the
three symptom domains of ADHD and provide summary
scores for each individual based on deviation from a nor-
mative data set based on age group and gender. There
are two versions of the task for children and young
people; the task for 6–11-year olds is 15 min duration
and the task for 12–17-year olds is 20 min duration. The
QbTest result is complemented by a clinical evaluation
and behavioural observation of events that may affect
test performance. The QbTest is not a stand-alone diag-
nostic tool, but has been approved by the US Food and
Drug Administration (FDA; Ref: K133382) to supple-
ment standard clinical assessment and treatment
follow-up by reducing reliance on measures such as sub-
jective observer reports (which can be biased, incom-
plete or missing) and augment clinical decision-making.
The data available about the QbTest has shown favour-
able psychometric characteristics with child participants.
For example, Qbtech report data that establishes 85%
sensitivity of classiﬁcation and 92% speciﬁcity, and good
test–retest scores, which is not inﬂuenced by experience
with computers (F Ulberstad, 2012, unpublished data).
Reh et al22 investigated the factor structure and concur-
rent and discriminant validity of QbTest and found the
hyperactivity factor correlated with teacher ratings of
hyperactive behaviour, providing evidence for the utility
of including this additional measure of activity in a CPT.
In addition, Reh et al23 found the hyperactivity factor
could identify intermediate levels of impairment in
ADHD siblings, suggesting this factor maybe particularly
sensitivity as an intermediate phenotype for ADHD.
Their ﬁndings also provide initial evidence for the con-
current validity of the three factors (attention, impulsiv-
ity and activity), although the authors highlight the
need for further research to investigate validity.
Wehmeier et al24 found QbTest to be a valid measure of
treatment outcome and highly correlated with blinded
observer ratings of behaviour in placebo-controlled ran-
domised controlled trial (RCTs). QbTest is effective in
evaluating ADHD medication effects in children25 26
and can identify early non-responders.15 One clinical
study found QbTest improved clinical accuracy by redu-
cing the risk of unidentiﬁed ADHD when patients were
re-evaluated 1 year after their initial assessment27 and
another indicated the ability for QbTest to differentiate
ADHD from normative controls.28 Initial audit data
(K Selby, 2013, unpublished data) suggest that imple-
mentation of QbTest in routine ADHD clinics can
reduce the time to diagnosis by 30%. This equates to a
reduction from an average of three to two out-patient
appointments per patient in order to either conﬁrm or
exclude a diagnosis of ADHD. These ﬁndings indicate
potential for QbTest to support the diagnostic assess-
ment and management of ADHD within routine clinical
practice; however, there has been no RCT to investigate
the added clinical value (clinical utility) and economic
cost-effectiveness of adding QbTest to standard ADHD
care pathways within the NHS.
The primary aim of the Assessing QbTest Utility in
ADHD-Trial (AQUA-Trial) is to determine whether
using QbTest in routine NHS settings can accelerate
diagnosis without compromising diagnostic accuracy.
Second, the study aims to examine whether QbTest
improves the medication titration process by increasing
the proportion of patients normalised after 6 months
postbaseline assessment and improves patient outcome.
The study will also use qualitative methods to explore
the barriers, drivers and facilitators to the adoption of
the QbTest in routine practice. The cost-effectiveness of
implementing the QbTest in practice will also be investi-
gated. The ﬁndings will indicate whether establishing
QbTest as part of standard practice in ADHD assessment
and management is clinically useful, ﬁnancially viable
and acceptable for clinicians and patients.
METHODS AND ANALYSIS
Trial design
This study is a parallel group single-blind multicentre
RCT, exploring feasibility and acceptability, using quanti-
tative and qualitative and health economic evaluations.
The study consists of two arms:
1. QbOpen (QbO): In this arm of the trial participants
will complete the QbTest and clinicians, participants
and their families will have immediate access to a
QbTest report.
2. QbBlind (QbB): In this arm of the trial participants
will complete the QbTest but the QbTest report will
be withheld from the clinician, participant and
patient’s family until the last outcome measure is
completed at 6 months. All participants will receive
the same intervention. Speciﬁcally, this will be assess-
ment as usual plus a QbTest as part of the diagnostic
assessment.
The patients usual care team will be responsible for
conducting the QbTest in clinic appointments. The
QbTest will be only be conducted by trained QbTest
clinicians.
Setting
Child and Adolescent Mental Health Services (CAMHS)
and Community Paediatric clinics across nine different
NHS Trusts in England, including Medway NHS
Foundation Trust, Alder Hey Children’s NHS Foundation
Trust, Nottinghamshire Healthcare NHS Trust,
Leicestershire Partnership NHS Trust, Sussex Partnership
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NHS Foundation Trust, United Lincolnshire Hospital
NHS Trust, Central Manchester University Hospitals NHS
Foundation Trust, Bridgewater Community Healthcare
NHS Trust, Nottingham University Hospitals NHS Trust.
Additional NHS Trusts may be recruited to meet target
recruitment ﬁgures.
Recruitment and eligibility
New referrals for a diagnostic evaluation for suspected
ADHD will be invited to participate in the research
based on the following criteria:
Inclusion criteria
▸ Age 6–17 years old (at the time of consent);
▸ Referred to CAMHS or Community Paediatrics for an
ADHD diagnostic assessment;
▸ Capable of providing written informed consent (over
16 years old);
▸ Parental consent (under 16 years old).
Exclusion criteria
▸ Severe learning disability (to be assessed by clinical
judgment);
▸ Non-ﬂuent English speaking;
▸ Previous or current conﬁrmed diagnosis of ADHD;
▸ Currently receiving ADHD medication.
Written information about the trial will be sent to fam-
ilies through the clinic administrators prior to their ﬁrst
appointment. Clinic invitations will be updated and
recorded on a password protected database on a weekly
basis. Parents and young people who wish to participate
will be asked to complete and return a consent form
before this appointment. Alternatively, participants will
be consented into the study by the clinical team, clinical
studies ofﬁcer or a member of the research team at
their ﬁrst appointment. Each site will be informed of
the monthly recruitment target required in order to
meet the study sample size and updated on their
monthly progress.
Trial phases
There are two phases to this study (ﬁgure 1).
Phase 1, Assessment: The ﬁrst phase investigates the
use of QbTest as a tool to aid diagnosis. Participants will
undergo ADHD ‘assessment as usual’, which varies
between clinics, clinicians and cases, but will typically
involve an interview with the parent/young person and
collection of questionnaires from the parent/young
person and teacher. While attending the clinic, the par-
ticipant will be asked to complete the QbTest at some
point during the diagnostic process. Participants will
also be asked to complete baseline outcome measures
(see measures section).
Phase 2, Treatment: Patients who receive a clinic diag-
nosis of ADHD and are allocated by clinicians to receive
ADHD medication initiated within 3 months of their
baseline assessment will be asked to complete a second
QbTest (Qb2) 4–8 weeks after medication initiation.
This timeframe was chosen to ensure that all
participants can complete their second QbTest before
the 6-month follow-up.
All participants will stay in the trial for 6 months and
will be asked to complete outcome measures at 3 and
6-month follow-up, regardless of their diagnosis or
whether they receive medication. With the aim of pro-
moting participant retention and completion of
follow-up measures, participants will be compensated for
their time with a £15 high-street voucher if they remain
in the trial until 6 months.
Measures
Blinded members of the research team (CLH, GMW,
AZV,) will be fully trained in all trial assessments and
responsible for monitoring the distribution, completion
and collection of all outcome measures.
Primary outcome
The primary outcome is the number of consultations
until a conﬁrmed clinical diagnosis is reached, as
recorded on a short pro-forma. The pro-forma will be
completed by clinicians after each consultation with the
young person and/or family and documents informa-
tion about appointment duration, diagnosis and medica-
tion/treatment. The pro-forma can be provided by
contacting the corresponding author.
Secondary outcomes
The secondary outcomes obtained from the pro-forma
are:
▸ Number of days and duration of visits (in minutes)
until a conﬁrmed diagnosis is reached.
▸ Clinical conﬁdence in diagnostic decision. Clinicians
will be required to rate the conﬁdence of their deci-
sion on a 7-point Likert scale (Deﬁnitely ADHD-
Deﬁnitely not ADHD).
▸ Stability in diagnosis. Clinicians will be required to
re-rate their diagnostic decision and conﬁdence at
6 months.
Other measures
▸ Development and Well-being Assessment (DAWBA29):
The DAWBA is a semistructured, investigator-based
diagnostic interview for child mental health pro-
blems, including ADHD, which includes the
(Strengths and Difﬁculties Questionnaire; SDQ30) as
an initial screen. The parent and teacher DAWBA will
be completed to compare the accuracy of clinic diag-
nosis (in QbO and QbB arms of the trial) to that of
an independent clinical consensus diagnosis made
using the DAWBA. Two experienced clinicians, blind
to allocation, will review the DAWBA and arrive at a
clinical consensus diagnosis.
▸ QbTest scores: Q-scores for attention, impulsivity and
activity will be compared with DAWBA ADHD diagno-
sis to obtain the best predictive model based on
QbTest scores that discriminates between ADHD
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‘positive’ and ADHD ‘negative’ gold standard
DAWBA diagnosis.
▸ Side-effects scale:31 Side-effects scale will be com-
pleted as a control check in medicated participants to
ensure greater speed to diagnosis/medication nor-
malisation is not off-set by greater side effects.
▸ SNAP-IV:32 The proportion of patients achieving
symptom normalisation assessed via the SNAP-IV. If
the young person receives a QbTest on medication
(Qb2), the timing on the 3-month SNAP-IV will be
moved to coincide with Qb2 to provide a direct com-
parison of subjective (SNAP-IV) and objective
(QbTest) measures. The SNAP-IV is a rating scale
designed to assess ADHD symptoms.
▸ SDQ:30 The SDQ is a brief behavioural screening
questionnaire which can be used as part of a clinical
assessment.
▸ C-GAS (Children’s Global Assessment Scale33):
Clinician opinion of patient outcome will be assessed
via the C-GAS. The C-GAS is a 0–100 scale which that
integrates psychological, social and academic func-
tioning in children.
▸ EQ-5D-Y (EuroQol Five Dimensions Heath
Questionnaire-Youth34): Child health-related quality
of life will be assessed using the EQ-5D-Y.
▸ A resource collection proﬁle tool will be used. It will
encompass elements of a CSRI (Client Service
Receipt Inventory35) often used in mental health
Figure 1 Study flow chart. ADHD, attention deficit/hyperactivity disorder; CAMHS, Child and Adolescent Mental Health
Services.
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studies but will be a speciﬁcally designed economic
collection pro-forma for the purpose of this study. It
will collect demographic details as well as information
on all the services used by the child and family borne
costs to be estimated. Indirect costs such as time lost
from work incurred by the child’s parents or carers
will further be recorded. This measure will enable a
societal wide perspective for a cost-effectiveness ana-
lysis of the QbTest. The DAWBA29 QbTest22 SDQ30
Side-effects scale,31 SNAP-IV32 C-GAS33 EQ-5D-Y34
and CSRI35 all have established reliability, validity and
history of use in clinical and research settings.
Feasibility and acceptability
QbTest opinion questionnaire and interview: Clinician
and patient opinion of the QbTest will be assessed via a
questionnaire, developed by CLH and currently used to
assess QbTest opinion in on-going studies at the Queens
Medical Centre, Nottingham. This will provide informa-
tion on the acceptability of QbTest in routine NHS set-
tings. A subsample (n=20) of families and clinicians will
be invited to participate in qualitative interviews to
further explore acceptability and feasibility of the QbTest.
The subsample will be chosen at random from each par-
ticipating site, using a random number generator.
Table 1 displays a summary of measures, the informant
and the time point of completion. All measures will have
a 1-month window for completion, with the exception of
the clinic pro-forma which must be completed during or
just after the clinic appointment and the QbTest which
must form part of the diagnostic or medication assess-
ment. The collected outcome measures for participants
who drop out the trial before 6 months will be included
in analysis, no further outcome measures will be col-
lected from these participants after they terminate their
participation.
Sample size and justification
The sample size calculation was based on an audit study
data from the Department of Community Pediatrics at
the Medway NHS Trust (K Selby, 2013, unpublished
data). Calculations based on this audit study data
showed that the mean number of visits needed to
achieve an ADHD diagnosis before introduction of the
QbTest (control rate) for children aged 6–14 year olds
was 2.94 visits and following the introduction of QbTest
a diagnosis was reached in a mean of 2.18 visits.
Following consultation with stakeholders, it was agreed
that this difference (2.94–2.18) represented the
minimum clinically important difference, with any
smaller difference in mean clinic visits being of debat-
able value. Therefore, 71 patients in each study group
will be required to detect a mean count difference of
the above magnitude with 80% power at two tailed 0.05
signiﬁcance level36 37 assuming the number of visits
follows a Poisson distribution.
Given the evidence that the intraclass correlation coefﬁ-
cients of mental health measures across General
Practitioner (GP) centres is extremely low,38–40 and results
from the Medway audit data indicate that the number of
visits needed to achieve an ADHD diagnosis was homoge-
neous across centres, we will assume that centre effects will
not inﬂuence the sample size calculation for this study.
After taking into account a 20% attrition rate, the ﬁnal
total sample size will be 178. The same calculation per-
formed with 90% power would require a total sample of
234 participants. We aim to recruit 178 participants as a
minimum and 234 participants as a maximum. Software
Stata V.13 was used for power analysis.
Randomisation and blinding
Once consent has been obtained from participants,
their information will be entered onto a web-based ran-
domisation system (set up by University of Nottingham
Clinical Trials Unit; CTU). The arm to which a partici-
pant is assigned will be determined by a computer gen-
erated pseudo-random code using random permuted
blocks of varying size, created by the Nottingham CTU
in accordance with their standard operating procedure
and held on a secure server. Participants will be
Table 1 Synoptic table of study measures
Measure Baseline
4–8 weeks after
medication initiation* 3 months 6 months
QbTest (C) x x
Pro-forma (C)† x x x x
C-GAS (C) x x x
DAWBA (P&T) x
SDQ (P&T) x x
SNAP IV (P&T) x x x x
EQ-5D-Y (P) x x x
CRSI (P) x x x
QbTest Opinion (C&P) x
Subsample clinician/family interview (n=20) x
*If ADHD diagnosis record and medicated within 3 months of baseline assessment (in place of corresponding 3 month assessment in grey).
†Completed at every appointment.
C, clinician completed; P, parent/carer completed; T, teacher completed.
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allocated with equal probability to each arm (QbO and
QbB) with stratiﬁcation by site. All participants will
undergo the same research measures, including the
QbTest. It is the time at which the report is made avail-
able to the clinician and patient that is randomised
(immediately vs 6 months later). Outcome assessors for
all measures will be blind to which arm the participant
is in. There are no anticipated events.
In which participant unblinding would be necessary.
There is an allocated unblinded research team member
(CKH) to provide control checks where required.
Data analysis plan
The analysis will be conducted on an intention-to-treat
(ITT) basis. Exploratory analysis will be conducted ﬁrst for
outcome and patient background variables; descriptive sta-
tistics of each variable will be presented separately for each
group at each follow-up point, with means and SD for nor-
mally distributed variables, medians (IQR) for skewed vari-
ables and frequency (percentage) for categorical
variables. Missing values will be checked and reported.
Multiple imputation will be used to hand missing values,
based on a multilevel modelling approach.
To compare the number of visits needed to achieve an
ADHD diagnosis (either conﬁrmed or excluded)
between groups, Poisson regression with binary group
status as the explanatory variable will be implemented. To
compare clinician’s conﬁdence in their diagnostic deci-
sions, multilevel modelling with patient as a level 2 unit
will be used to take into account the non-independence
within patient data due to repeated measures.41
κ Statistics will be used to reﬂect the stability of diagno-
sis between ﬁrst conﬁrmed diagnosis and diagnosis
rerated at 6-month follow-up time. κ Statistics will be
reported for each group and the stability of diagnosis will
be compared between arms using logistic regression. The
same analysis approach will be implemented to explore
the stability of diagnosis conﬁdence between time of ﬁrst
conﬁrmed diagnosis and 6-month follow-up. To assess the
diagnosis accuracy, the sensitivity, speciﬁcity, likelihood
ratio (LR) ve+, LR ve−, positive predictive value (PPV)
and negative predictive value (NPV) will be reported for
each group and the test performance will be compared
between QbO and QbB arms.42 43 Receiver operating
characteristic curve analyses will be used to obtain the
best predictive model based on QbTest scores that discri-
minates between ADHD ‘positive’ and ADHD ‘negative’
gold standard DAWBA diagnoses.
For treatment related outcomes (phase 2) outcome
measures such as SNAP-IV, side effects scale, SDQ and
C-GAS scores, multilevel modelling with patient as a
level 2 unit will be again applied to quantify the differ-
ence between QbO and QbB arms.
For time to event variables such as time to diagnosis
(in days), survival analysis using log-rank test will be per-
formed for group comparison and Kaplan-Meier survival
curves will be displayed for each group. Logistic regres-
sion will be used to compare the proportion of
normalisation between two groups at 6-month follow-up
time. For all regression modelling to explore the differ-
ence between arms, group status will be included as
explanatory variables. Data transformation would be
needed for skewed outcome variables.
Health economic evaluation
Economic evaluation will be completed primarily from a
health service perspective but in addition from a societal
perspective. A cost-effectiveness and cost utility analysis
of the treatment options will be conducted. This will
include incremental cost-effectiveness ratio of QbTest
versus usual care; and present cost-effectiveness accept-
ability curves (CEACs) for the diagnostic/treatment
options. CEACs enable a probabilistic visual interpret-
ation of the health economic analysis that can be used
by decision-makers to assist in their choice of health
service delivery.
Implementation
To assess feasibility and acceptability we shall look at
scores on the QbTest feedback questionnaires. High
scores will be taken to indicate high acceptability and
feasibility. Mean scores for individual items on each
questionnaire will be assessed to determine which
aspects of QbTest are perceived negatively or positively
by clinicians and service users. Data from clinicians and
patients who participate in interviews will be thematically
analysed according to the principles of Braun and
Clarke44 to assess themes on the acceptability of QbTest,
including patients’ opinion on reduced length or
number of clinic visits.
Data monitoring
No interim analysis or analyses for safety or efﬁcacy are
planned. Access to data will be restricted to trial team
members and associated regulatory authorities as indi-
cated in the sponsor agreement between sites and indi-
vidual participant information sheets. The chief
investigator (CH) shall oversee study management, with
oversight from the rest of the research team. A sample
(10% of the data) will be checked on a regular basis for
veriﬁcation of all entries made. Where corrections are
required these will carry a full audit trail and justiﬁca-
tion, independent from the research team. There are no
anticipated adverse effects of the QbTest, all adverse
events will be recorded and monitored and the CH will
determine seriousness and causality and report the
event to the ethics committee.
The trial is overseen by an independent CLAHRC East
Midlands Scientiﬁc Committee. The members of the com-
mittee are drawn externally from outside the institutions
of the research team members and the trial sponsor.
STUDY LIMITATIONS
The diagnosis and management of ADHD is inconsistent,
as such the ‘assessment as usual’ practice will vary across
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sites. In order to document this difference each site com-
pleted a questionnaire prior to their participation in the
trial detailing their ‘assessment as usual’ procedure.
Furthermore, basic descriptions of ‘assessment as usual’
will be recorded in the pro-forma (such as number and
length of appointments, decision-making and medica-
tion). Given this is a pragmatic trial conducted in real-
world settings we are interested in the impact of adding
QbTest feedback to ‘assessment as usual’—without chan-
ging other aspects of practice. In order to minimise the
trial results being inﬂuenced by practice in any one site,
we are recruiting participants across multiple sites in dif-
ferent regions of the country and include both CAMHS
and community paediatrics. In our design, we have
attempted to control for variations between sites by strati-
ﬁcation of randomisation by site.
ETHICS AND DISSEMINATION
Patient recruitment has started at these sites and add-
itional R&D approvals at other sites are in progress. The
study is sponsored by the University Of Nottingham;
neither the sponsor nor the funders will be involved in
the analysis of study data or report writing. QbTech will
provide QbTest reports to the study team, which will be
analysed by BG, from the University Of Nottingham.
Only the research team will have access to the study
data, data generated from the trial will be available for
inspection by the ethics and R&D committees on
request. Changes to the protocol will be communicated
to the ethics committee by the lead research fellow
(CLH). The process for obtaining participant informed
consent or assent and parent/guardian informed
consent will be in accordance with the ethical guidance,
and Good Clinical Practice. The investigator or their
nominee and the participant or other legally authorised
representative (such as the child’s parent) shall sign and
date the informed consent forms (see online supple-
mentary appendix A and B) before the person can par-
ticipate in the study. Written consent will be required
from young people aged 16 years and above and their
parents. If the young person is under 16 years of age,
parental consent will be required, with the young
person’s written or verbal assent. Individual participant
medical information obtained as a result of this study
are considered conﬁdential and disclosure to third
parties is prohibited unless warranted by an adverse
event. Participant conﬁdentiality will be further ensured
by utilising identiﬁcation code numbers to correspond
to treatment data in the computer ﬁles. No post-trial
care is required.
The primary aim of this study is to determine whether
using QbTest in routine NHS settings can accelerate
time to correct diagnosis, with a secondary aim of exam-
ining whether the QbTest can improve patient outcome.
Currently, there are few trials conducted in routine NHS
settings with the aim of improving the ADHD care
pathway, despite evidence to suggest suboptimal care
standards and rising socioeconomic burdens. The ﬁnd-
ings of this study will help to demonstrate whether the
QbTest is clinically useful and ﬁnancially viable in stand-
ard care. The ﬁndings of the trial will be submitted for
publication in appropriate journals regardless of
outcome (in accordance with the recommendations of
CONSORT) and to members of the public.
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